Category · 30 entries
Pipeline & In-Development
Compounds in late-stage clinical trials or under FDA review — not yet available as approved medicines.
Amycretin
Novo Nordisk's investigational single-molecule GLP-1 and amylin receptor agonist, tested as a daily tablet and a weekly injection: in a phase 1b/2a trial the 60 mg weekly dose gave a mean weight change of -24.3% at 36 weeks against -1.1% on placebo. Not approved anywhere.
Apitegromab
⚠ Monoclonal antibody, not a peptide. Scholar Rock's antibody against the proforms of myostatin, FDA-approved on September 11, 2026 as Isembyld for spinal muscular atrophy in patients 2 and older already on an SMN2-targeted treatment.
Apraglutide
Ironwood's weekly GLP-2 analog for short-bowel syndrome — STARS Phase 3 positive (2024), NDA submitted to FDA 2025; potentially the first once-weekly SBS therapy and a meaningful improvement over teduglutide's daily dosing.
AZD6234
AstraZeneca's long-acting amylin analog — Phase 2 in obesity (2024) — part of AZ's entry into the GLP-1-adjacent obesity space alongside ECC5004; analogous in mechanism to cagrilintide.
Bimagrumab
The activin receptor antibody that adds muscle and removes fat: failed in a muscle disease, now paired with semaglutide for obesity.
CagriSema
Novo Nordisk's next-generation obesity injection — NDA filed December 2025, FDA review expected 2026. If approved, it would be the first GLP-1 + amylin fixed-dose combination and a direct competitive response to tirzepatide.
Cotadutide
A GLP-1 and glucagon dual agonist that reached phase 2b in diabetes, kidney and liver disease before AstraZeneca stopped it in 2023.
Danuglipron
⚠ Not a peptide — small molecule. Pfizer's discontinued oral GLP-1 program — halted April 14, 2025 after a single case of potential drug-induced liver injury in a once-daily dose-optimization study, ending Pfizer's second oral GLP-1 failure in as many years. Included in this peptide encyclopedia because the audience frequently searches for it alongside peptide GLP-1 agonists.
ECC5004
An oral small-molecule GLP-1 receptor agonist, not a peptide, developed by Eccogene and then AstraZeneca; a phase 3 trial registered in 2026 names it elecoglipron.
Efpeglenatide
A weekly-to-monthly exendin-4-based GLP-1 agonist with positive Phase 3 cardiovascular outcomes (AMPLITUDE-O, 2021) — Sanofi returned the license to Hanmi in 2020; Hanmi re-partnered with Innovent in 2020 for China development and with Kailera in 2024 for global development.
Eftansomatropin alfa
Genexine and Handok's long-acting growth hormone, somatropin fused to a hybrid Fc; in development, with a Chinese licence application filed and no approval found as of October 2026.
Elsiglutide
Zealand Pharma's early GLP-2 analogue (ZP1846), tested in phase 2 for chemotherapy-induced diarrhoea; no later trials are known.
Garetosmab
An anti-activin A antibody approved in 2026 for fibrodysplasia ossificans progressiva, after a phase 2 that missed its primary endpoint.
Glepaglutide
A once- or twice-weekly GLP-2 analogue for short bowel syndrome whose phase 3 met its endpoint on the twice-weekly dose.
GMA106
Gmax Biopharm's anti-GIPR antibody fused to a GLP-1 peptide, in development for obesity; one completed Phase 1 trial, no published results.
HM15136
A weekly glucagon analogue in early trials for congenital hyperinsulinism, where raising blood sugar is the point.
HM15275
Hanmi's triple-agonist GLP-1/GIP/glucagon candidate, mechanistically analogous to retatrutide — Phase 2 in obesity with a monthly-dosing ambition enabled by Hanmi's LAPSCOVERY platform.
HRS-9531
Hengrui's once-weekly GLP-1/GIP dual agonist in Phase 3 in China for obesity, with Kailera Therapeutics holding global ex-China rights since 2024; the structurally closest Chinese competitor to tirzepatide.
Insulin efsitora alfa
Lilly's once-weekly basal insulin, an insulin variant fused to an antibody Fc fragment, FDA-approved in September 2026 as Onswik for adults with type 2 diabetes after four QWINT trials found HbA1c lowering non-inferior to daily basal insulin.
KN056
Alphamab's GLP-1 / glucagon dual agonist — an early-clinical Chinese entry in the GLP-1/glucagon mechanism space pioneered by cotadutide and now represented by pemvidutide and survodutide.
Maridebart cafraglutide
Amgen's once-monthly obesity injection — Phase 3 MARITIME program underway, ~20% weight loss at 52 weeks in Phase 2 (NEJM 2025), approximately 21-day half-life enabling monthly or less frequent dosing.
PB-718
PegBio's dual GLP-1 / GLP-2 agonist — an unusual combination targeting both the incretin axis and intestinal mucosal trophic signaling; Phase 2 in T2DM and NAFLD.
Pemvidutide
Altimmune's GLP-1 / glucagon co-agonist — received FDA Breakthrough Therapy Designation for MASH in January 2026 after positive IMPACT Phase 2b antifibrotic data, with Phase 3 initiation planned for 2026.
Petrelintide
Zealand's weekly amylin analogue, built to mix with other drugs and tested alone in a 42-week phase 2 obesity trial.
Relamorelin
A ghrelin-agonist pentapeptide for diabetic gastroparesis: positive phase 2 trials, then all five phase 3 trials terminated in 2020 on a business decision.
Tabimorelin
Novo Nordisk's oral growth hormone secretagogue (NN703): GH rose in healthy men, but not beyond placebo in GH-deficient adults, and it inhibits CYP3A4. Discontinued.
Taldefgrobep alfa
Biohaven's anti-myostatin adnectin-Fc fusion: its Duchenne programme ended in 2019 after a futility analysis, and its phase 3 RESILIENT trial in SMA missed its primary endpoint in November 2024.
Taspoglutide
A once-weekly GLP-1 RA co-developed by Ipsen and Roche — Phase 3 halted in 2010 after unacceptably high rates of injection-site reactions and hypersensitivity (including systemic allergic reactions), making it the most prominent immunogenicity-driven failure in the GLP-1 class.
Trevogrumab
⚠ Monoclonal antibody — not a classical peptide. A Regeneron anti-myostatin fully human IgG (~150 kDa) being tested as a muscle-sparing adjunct to GLP-1 therapy — CONVERGE combination program with semaglutide in obesity; earlier sarcopenia programs were deprioritized in favor of the obesity opportunity. Included here because it's widely discussed alongside peptides in muscle-sparing conversations.
VK2735
Viking's emerging dual GLP-1/GIP agonist — Phase 2 SC data in obesity reported up to ~14.7% placebo-adjusted weight loss at 13 weeks (VENTURE, 2024), with an oral-tablet Phase 2 program initiated 2024; the principal clinical challenger to tirzepatide's mechanism outside the Lilly / Novo axis.